NSAIDs vs. Coxibs in the Presence of Aspirin
4期
提前终止
NCT03699293
| 适应症 | Rheumatoid Arthritis, Cardiovascular Diseases |
|---|
| 分期 | 4期 |
|---|
| 申办方 | Platelet and Thrombosis Research, LLC |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 8 人 |
|---|
| 干预（药物） | celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet |
|---|
| 开始日期 | 2018年9月22日 |
|---|
| 完成日期 | 2022年12月1日 |
|---|
| 结果公布日 | 2026年5月14日 |
|---|
摘要
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
Change in Arachidonic Acid (AA)-Induced Platelet Aggregation
End of 4-week aspirin run-in period and after completion of each 4-week treatment period · Percent Aggregation (%)
| Sequence 1: 1) Aspirin Run in Period, 2) ASA + Celecoxib, 3) ASA + Naproxen Sodium | 2.5 ± 0.7 Percent Aggregation (%) |
|---|
| Sequence 2: 1) Aspirin Run in Period, 2) ASA + Naproxen Sodium, 3) ASA + Celecoxib | 3.3 ± 4.9 Percent Aggregation (%) |
|---|
| Sequence 1: 1) Aspirin Run in Period, 2) ASA + Celecoxib, 3) ASA + Naproxen Sodium | 1.4 ± 1.6 Percent Aggregation (%) |
|---|
| Sequence 2: 1) Aspirin Run in Period, 2) ASA + Naproxen Sodium, 3) ASA + Celecoxib | 3 ± 0 Percent Aggregation (%) |
|---|
| Sequence 1: 1) Aspirin Run in Period, 2) ASA + Celecoxib, 3) ASA + Naproxen Sodium | 6.5 ± 7.8 Percent Aggregation (%) |
|---|
| Sequence 2: 1) Aspirin Run in Period, 2) ASA + Naproxen Sodium, 3) ASA + Celecoxib | 31.5 ± 34.6 Percent Aggregation (%) |
|---|
Change in Collagen-induced Platelet Aggregation (%)
End of 4-week aspirin run-in period and after completion of each 4-week treatment period · Percent Aggregation (%)
| ASA Lead in Followed by ASA + Celecoxib, and Then Crossover to ASA+ Naproxen Arm. | 55.3 ± 20.4 Percent Aggregation (%) |
|---|
| ASA and Naproxen | 68.0 ± 18.4 Percent Aggregation (%) |
|---|
| ASA Lead in Followed by ASA + Celecoxib, and Then Crossover to ASA+ Naproxen Arm. | -0.3 ± 3.7 Percent Aggregation (%) |
|---|
| ASA and Naproxen | -12.5 ± 14.8 Percent Aggregation (%) |
|---|
| ASA Lead in Followed by ASA + Celecoxib, and Then Crossover to ASA+ Naproxen Arm. | -10.7 ± 8.2 Percent Aggregation (%) |
|---|
| ASA and Naproxen | -6 ± 3.1 Percent Aggregation (%) |
|---|
Change in Adenosine Diphosphate (ADP)-Induced Platelet Aggregation (%)
End of 4-week aspirin run-in period and after completion of each 4-week treatment period. · Percent Aggregation (%)
| ASA and Celecoxib | 60.3 ± 11.0 Percent Aggregation (%) |
|---|
| ASA and Naproxen | 64.0 ± 14.4 Percent Aggregation (%) |
|---|
| ASA and Celecoxib | -27 ± 22 Percent Aggregation (%) |
|---|
| ASA and Naproxen | 0.5 ± 0.7 Percent Aggregation (%) |
|---|
| ASA and Celecoxib | -6.6 ± 6.7 Percent Aggregation (%) |
|---|
| ASA and Naproxen | -3 ± 8.5 Percent Aggregation (%) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。